Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival
Categories
Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus according to findings of RTOG 0436, a randomized phase III trial presented by David Ilson, MD, of Memorial Sloan Kettering Cancer Center, at the 16th World Congress of Gastrointestinal Cancer on June 26, 2014.
http://www.onclive.com/conference-coverage/world-GI-2014/Adding-Cetuximab-to-Chemoradiation-in-Non-operable-Esophageal-Cancer-Does-Not-Improve-Survival